|
|
|
9th Global Drug Delivery & Formulation Summit |
 |
|
12-14 March 2018
Maritim proArte Hotel Berlin
The growth of biopharma, patient compliance issues and ever
increasing regulatory requirements have encouraged us to adopt a drug delivery
mind set from discovery through to production.
Every year we see innovation and breakthroughs at all levels
of drug and formulation development. From big pharma, through the smaller
biotechnology companies all the way to university research teams and spin outs.
The DDF Summit brings the most interesting studies and
exciting technologies to you. This year there will be 4 dedicated streams
focusing on Small Molecules, Biologics, Technology & Innovation and for the
first-time Device Development.
You’ll find new technologies, concepts and case studies in
areas such as… • Less traditional delivery routes including nasal, ocular & subcutaneous
• Targeted and controlled release technologies and nanoparticles
• Increasing stability of amorphous solid dispersion
• QbD in biopharmaceutical development
• Formulation strategies for multiple injection dosing
• Oral delivery of peptides
• Continuous manufacturing and processing for improved efficiency
• User friendly technologies for improving patient convenience and
compliance
• Regulatory strategies for combination products
• Drug stability and material selection in combination products
Visit www.ddfevent.comor contact maxconferences@markallengroup.comfor more information. |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
Pharma and Device Packaging and Labelling West Coast 2018
27-28 November 2018, Burlingame, CA
The second edition of the Pharma and Device Packaging and
Labeling West Coast was a thought-provoking two days of engaging presentations,
discussion and networking.
More info >> |
|
 |
White Papers |
 |
|
Recommendations for Implementing Assessment Criteria Guidelines in Lymphoma and Chronic Lymphocytic Leukemia Clinical Trials
Perceptive Informatics
Standardized assessment criteria are becoming increasingly important in obtaining valid outcomes in oncology clinical trials. While standardized criteria encourage a more uniform approach to assessing clinical trial data, they are often subject to the interpretation of the user. These differences in interpretation, while seemingly minor, can have a major impact on assessments. The most commonly used standardized criteria for lymphoma have been no exception. Differences such as minimum new lesion size, lymph node normalization size requirements, inclusion of extranodal lesions and assessment of organomegaly can have a profound effect on overall response. Additionally, heightened scrutiny of the assessment criteria used in a given protocol can lead to questions about a drug’s efficacy if not applied correctly according to regulators’ interpretation.
More info >> |
|
 |
News and Press Releases |
 |
BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio
BioIVT,
a leading provider of research models and services for drug development, today
announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and
its comprehensive portfolio of transporter assays, multi-transporter models,
transporter systems biology, and molecular transport research solutions.
More info >> |
|
|
